Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 53.3% in December

Repare Therapeutics Inc. (NASDAQ:RPTX) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 1,300,000 shares, a growth of 53.3% from the December 15th total of 847,800 shares. Based on an average daily volume of 380,100 shares, the short-interest ratio is currently 3.4 days. Approximately 4.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of RPTX. Vontobel Holding Ltd. raised its stake in Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares in the last quarter. Bank of Montreal Can raised its position in shares of Repare Therapeutics by 5.4% during the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after buying an additional 5,673 shares in the last quarter. Barclays PLC raised its position in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after buying an additional 7,800 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after acquiring an additional 8,809 shares during the last quarter. Finally, Stifel Financial Corp grew its position in Repare Therapeutics by 36.4% in the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after acquiring an additional 13,800 shares in the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Price Performance

NASDAQ RPTX remained flat at $1.28 during trading on Friday. The company’s stock had a trading volume of 189,282 shares, compared to its average volume of 500,189. The stock has a 50 day moving average of $2.28 and a two-hundred day moving average of $2.97. Repare Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $8.49. The company has a market capitalization of $54.41 million, a PE ratio of -0.64 and a beta of 0.88.

Analyst Ratings Changes

RPTX has been the subject of a number of recent analyst reports. Lifesci Capital reaffirmed a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th. Stifel Nicolaus decreased their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, Bloom Burton downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.